Corbus Pharmaceuticals reported promising results Thursday from an early stage clinical study of a potential anti-inflammatory drug for people with cystic fibrosis. Researchers believe that reducing excessive inflammation in people with CF will reduce lung damage and slow progression of the disease.
The synthetic drug anabasam (formerly known as Resunab) demonstrated in a Phase 2 trial that it was safe and well-tolerated at all doses with no serious or severe adverse events, according to Corbus.
In the 16-week trial involving 85 participants, results demonstrated that anabasum (pronounced ah-NAH-bah-som) reduced multiple markers of inflammation including both inflammatory cells and mediators (chemicals that trigger an exaggerated immune response). Just as important, the drug did not show signs of suppressing the immune response, which has been a problem with other potential CF anti-inflammatories.
Although this is an early study, the results also suggest a potential clinical benefit. Participants in the trial who took the highest dose had a significant reduction in the annualized rate of pulmonary exacerbations compared to those on the placebo.
These results are considered to be encouraging for an early stage trial and support the continued development of anabasum as a potential anti-inflammatory in cystic fibrosis.
Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, provided a $5 million award to support the clinical trial.
For more information, see the Corbus press release.